Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn's disease
Background Muscle wasting or sarcopenia arising from chronic inflammation is found in 60% of patients with Crohn's disease. Transcriptional protein NF-κB reduces muscle formation through MyoD transcription and increases muscle breakdown by proteolysis. Aim As TNF is a potent activator of NF-κB, and anti-TNF agent infliximab (IFX) prevents NF-κB activation, to determine whether or not Crohn's patients treated with IFX gain muscle volume and strength. Methods We performed a...[Show more]
|Collections||ANU Research Publications|
|Source:||Alimentary pharmacology & therapeutics|
|01_Subramaniam_Infliximab_reverses_2015.pdf||482.77 kB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.